Nanobiotix (NBTX), a French clinical-stage biotechnology company focused on cancer, announced Monday a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, affiliated to Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). The deal is for the investigational, potential first-in-class radioenhancer NBTXR3.
from RTT - Before the Bell https://ift.tt/KqtPgNI
via IFTTT
No comments:
Post a Comment